CBRN Tactical

Operational premise: voluntary take-back creates custody. It does not create fitness for use.

A component recovered from an injector, drone or field device may look reusable, but visual similarity is not evidence. In CBRN-adjacent equipment, the distance between “returned” and “released” must be protected by traceable component evidence and a defined reuse gate.

1. Start with segregation

Every item entering a voluntary take-back stream should remain physically and digitally separate from approved stock. The record should identify source, material, known service history and any unresolved contamination or storage condition. Unknown status is a quarantine state, not permission to proceed.

2. Build component evidence

Component evidence should combine identity, inspection, measured characteristics, test method, rejection threshold and reviewer. A single passing measurement cannot establish fitness for every application. The proposed next use must be stated first, and the test boundary must match that use.

For example, a recovered spring may be screened for a narrowly defined, non-critical check-valve experiment. That does not justify direct transplantation, flight use or equivalence to an OEM component. Chemical compatibility, fatigue, dimensions, preload and failure consequence remain separate gates.

3. Make the reuse gate explicit

1. Reject: identity, contamination status or critical dimensions cannot be established.
2. Research-only: evidence is sufficient for a controlled bench experiment with simulants, not field release.
3. Restricted use: a qualified reviewer authorises a bounded, non-critical use under documented controls.
4. Recycle or dispose: the item follows the authorised material or waste route.

The reuse gate prevents a sustainability objective from becoming a safety shortcut. It also makes programme performance auditable: a voluntary take-back system should report how many items reached each disposition, what component evidence supported the decision, and which reuse gate rejected the remainder.

Read the UAM KoreaTech evidence-chain analysis.

As of 13 September 2026. Concept illustration. Simulants and substitute surfaces only. No live agents or hazardous materials. This is not engineering release, OEM approval, regulatory certification or direct-transplant guidance.